Mylan Gets PTAB To Nix Sanofi's Lantus Patent Claim
Mylan has successfully persuaded the Patent Trial and Appeal Board that one claim of a Sanofi-Aventis patent covering the Lantus SoloStar disposable insulin injection pen is invalid as obvious....To view the full article, register now.
Already a subscriber? Click here to view full article